Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 3/20 | 0.57 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.57 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.57 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099447 | 0.90 | ABCC9 (0.55) | ABCC9ABCC8KCNJ11KCNJ8CACNA1F | |
| SCHEMBL3022755 | 0.81 | ABCC9 (0.69) | ABCC9ABCC8KCNJ11KCNJ8ABCC1 | |
| SCHEMBL7016978 | 0.77 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL7594699 | 0.74 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CACNA1F | |
| SCHEMBL8214827 | 0.72 | ABCC9 (0.57) | ABCC9ABCC8KCNJ11KCNJ8ABCC1 | |
| SCHEMBL7573282 | 0.71 | ABCC9 (0.57) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL27692028 | 0.68 | KDM4E (0.51) | ACHEKDM4EALDH1A1TSHRCASP1 | |
| SCHEMBL7101141 | 0.67 | ABCC9 (0.47) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL3024530 | 0.67 | TSHR (0.53) | ABCC9ABCC8KCNJ11KCNJ8ABCC1 | |
| SCHEMBL3030945 | 0.67 | ABCC1 (1.00) | ABCC1CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307453-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020099070-A1 | Dihydronaphthyridine potassium channel openers | ABBOTT LABORATORIES | 2002-07-25 | — | — | US | claimed |
| WO-2002010164-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-02-07 | — | — | WO | claimed |
| EP-1307453-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020099070-A1 | Dihydronaphthyridine potassium channel openers | ABBOTT LABORATORIES | 2002-07-25 | — | — | US | disclosed |
| WO-2002010164-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099070-A1 | Dihydronaphthyridine potassium channel openers | KCNH1, KCNN1, KCNJ2 | ABCC9 440/4885ABCC8 645/4885KCNJ11 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.